Apotex Inc, a Canada-based global health company, announced on Friday that Health Canada has approved Apo-Semaglutide InjectionTM, a generic equivalent of Ozempic (semaglutide injection).
Apotex is the first Canada-based pharmaceutical company to gain authorisation for a generic equivalent of Ozempic. Semaglutide Injection will be the first Canadian generic equivalent to offer both the 2 mg/pen (0.68mg/mL) and 4 mg/pen (1.34 mg/mL) pen formats commercially, aligning with all brand equivalent SKUs.
Developed in partnership with Orbicular Pharmaceutical Technologies, Semaglutide Injection has undergone Health Canada's standard regulatory review for peptide medicines.
In Canada, semaglutide injection is indicated for the once-weekly treatment of adults with type 2 diabetes mellitus to improve glycaemic control, in combination with diet and exercise.
Apotex receives Health Canada approval for a generic Ozempic equivalent
Cirius Therapeutics introduces gestational diabetes initiative
Boehringer Ingelheim's survodutide phase 3 data show significant weight loss in obesity trial
AOTI reports strong real-world outcomes for TWO2 wound therapy
Ascletis completes enrolment for US Phase II study of ASC30 in diabetes
Renalytix advances kidneyintelX.Dkd scale-up with laboratory expansion and CE submission
FDA expands approval of Sanofi's Tzield for early-stage type 1 diabetes in young children
EKF Diagnostics acquires Beep Insights technology to expand sports performance offering
Apotex's generic Ozempic (Semaglutide Injection) receives US FDA tentative approval